Vergent Bioscience Secures $21.5 Million Series B Financing To Advance Clinical Development Of Tumor-Targeted Fluorescent Imaging Agent Vgt-309

Oct 04, 2022•almost 3 years ago

Amount Raised

$21.5 Million

MinneapolisBiotechnology

Description

Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, today announced the close of a $21.5 million Series B financing. Vergent will use the funds to advance clinical development of VGT-309, the company’s targeted fluorescent imaging agent that enables surgeons to see previously undetected or difficult-to-find tumors in real-time, ensuring all tumor tissue is removed during open, minimally invasive (MIS) and robotic-assisted surgical procedures.

Company Information

Company

Vergent Bioscience

Location

5810 W 78TH ST

Minneapolis, Minnesota, United States

About

Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors. Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors. Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.

Related People

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech